Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cordex Obtains FDA’ Special Protocol Assessment Approval For ATPace
Cordex Pharma has announced that FDA has approved the design of Phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhytmic drug for the treatment of
Cordex Pharma has announced that FDA has approved the design of Phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhytmic drug for the treatment of
Concert Pharmaceuticals and GlaxoSmithKline have formed an alliance to develop and commercialize deuterium-containing medicines. The deal includes three of Concert’s research and development programs, CTP-518, a protease inhibitor
Lamictal XR is approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalization. Lamictal XR reduced the frequency of
Results of phase Ib clinical trial for L-CsA, inhaled liposomal cyclosporine A, were published in Journal of Aerosol Medicine and Pulmonary Drug Delivery. L-CsA is delivered via an
Schering Plough has announced that the European Medicines Agency (EMEA) has validated the marketing authorization application (MAA) for Sycrest (asenapine) sublingual tablets for the treatment of schizophrenia and
NeurogesX has declared that the Office of Orphan Product Development (OOPD) of the FDA has granted orphan drug designation for Qutenza (formerly NGX-4010), a high concentration capsaicin dermal
The AmerisourceBergen has purchased Innomar Strategies, a Canadian specialty pharmaceutical services company, for approximately C$15 million ($13.8 million) in cash, subject to a working capital adjustment. David Yost,
AOE or “swimmer’s ear” is a common childhood infection of the ear canal characterised by intense pain and inflamed, damaged skin. AOE treatment should address three main goals
The study will directly compare the two basal insulins in an exclusively once daily regimen. Outcomes measured in the study will include efficacy, effect on weight and hypoglycaemia
The appeals court also reversed a sanctions determination against Medtronic, finding that it was legally incorrect and could not be sustained. The appeals court affirmed an award of